HPTN IN THE NEWS

New WHO Guidelines Recommend Universal Antiretroviral Treatment, PrEP for Those at Substantial Risk

This early-release guideline makes two key recommendations available that were developed during the revision process in 2015. The recommendations in this guideline will form part of the revised consolidated guidelines on the use of ARV drugs for treating and preventing HIV infection to be published by WHO in 2016. Multiple HPTN studies ([046], [052], [067], and [071]) are discussed in the guidelines. Read more.

SPOTLIGHT ON THE COMMUNITY

HPTN/MTN Community Writing Workshop

Upcoming Events

HPTN Regional Meeting
Oct. 24-25
Cape Town, South Africa

APHA
Oct. 31-Nov. 4
Chicago, Ill.

ICASA
Nov. 8-13
Hammamet, Tunisia

International Conference on HIV/AIDS, STDs & STIs
Nov. 30-Dec. 2
Atlanta, Ga.

National HIV Prevention Conference
Dec. 6-9
Atlanta, Ga.

CROI
Feb. 22-25
Boston, Mass.

Study Updates

HVTN 703/HPTN 081
HVTN 703/HPTN 081, also known as AMP (Antibody Mediated Prevention), is a Phase 2b clinical trial to evaluate the safety, efficacy and immunogenicity of VRC01, a broadly neutralizing monoclonal antibody (bNab) in reducing acquisition of HIV-1 infection.

Subscribe to our email list
360's Durham office for a weeklong writing workshop to enhance their manuscript writing skills. The workshop is expecting to produce 12 new manuscripts!

Musonda Simwinga, who works on HPTN 071 in Zambia said the workshop taught him a lot. "I really learned that we need to tell the community engagement story to the rest of the world," he said. "And what better place to tell it (through our writing) because we are the frontline people in the community." View photos.

---

**SPOTLIGHT ON NETWORK MEMBERS**

**Conversations With the HPTN**

How did you first become involved with the HPTN?

When I was at the Division of AIDS/NIAID (1988-1994), I co-wrote the RFA that resulted in the domestic and international HIVNET grants. Coming into academia, I was recused from working with HIVNET for several years to avoid conflict of interest. But when Ward Cates and Steve Self started to mobilize for a response to the new HPTN RFA, as a partial successor to HIVNET, they invited me to an organizational meeting in a scenic Chicago O’Hare airport conference room (no windows at all) and I was most pleased to accept this invitation! Read more.

---

**HOT OFF THE PRESS**


---

The study is expected to begin in November. Read more.

**HPTN 082**

HPTN 082 is a prospective study that will assess PrEP acceptance, adherence, acceptability, and continuation among a cohort of 400 HIV negative women ages 16 to 25 at three sites in southern Africa. The study is expected to begin in 2016. Read more.

**HPTN 083**

HPTN 083 is a Phase 2B/3 double-blind randomized study that will assess the efficacy of quarterly injections of cabotegravir (CAB LA) for PrEP among 4,500 HIV-uninfected MSM and transgender women who have sex with men by comparing it with daily oral PrEP (FTC-TDF). The study is expected to begin in 2016 at research sites located in the Americas and Asia. Read more.

---

**Awareness Days**

Follow us on social media

NEWSLETTER CHANGES

Based on feedback from the recent communications survey, we are now distributing the newsletter each month to ensure the Network stays well-informed and involved.

What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Share this email:

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

359 Blackwell Street, Suite 200
Durham, NC | 27701 US

This email was sent to.
To continue receiving our emails, add us to your address book.